Barry Greene
Barry Greene, Sage Therapeutics’ new CEO, is recognized for fostering sustainable, inclusive, and high-performing teams, earning strong confidence from colleagues in his commercialization leadership.
With a background at Alnylam where he developed the salesforce and forged critical partnerships, Greene is well equipped to guide Sage’s shift from biotech to profitability.
Greene’s approach centers on broadening opportunities, managing trial results, and optimizing reimbursement, prioritizing promising drugs such as Zuranolone and SAGE-718.
By submitting this form, you are agreeing to ManagementTrack’s Privacy Policy. You can choose to opt out of marketing or advertising emails using the ‘unsubscibe’ link included in our emails.
The best
The best
The best
Our investigative journalists interview the top former colleagues of the CEOs you care about.
Our former buysider analysts summarize the key strengths & weaknesses, past successes & failures, and ability to drive value going forward.
You get access to the actual anonymized transcripts and insights.